全文获取类型
收费全文 | 9264篇 |
免费 | 732篇 |
国内免费 | 19篇 |
专业分类
耳鼻咽喉 | 114篇 |
儿科学 | 316篇 |
妇产科学 | 212篇 |
基础医学 | 1193篇 |
口腔科学 | 43篇 |
临床医学 | 1237篇 |
内科学 | 1423篇 |
皮肤病学 | 222篇 |
神经病学 | 1147篇 |
特种医学 | 201篇 |
外科学 | 901篇 |
综合类 | 122篇 |
一般理论 | 5篇 |
预防医学 | 1348篇 |
眼科学 | 138篇 |
药学 | 629篇 |
中国医学 | 10篇 |
肿瘤学 | 754篇 |
出版年
2024年 | 25篇 |
2023年 | 133篇 |
2022年 | 202篇 |
2021年 | 485篇 |
2020年 | 243篇 |
2019年 | 385篇 |
2018年 | 468篇 |
2017年 | 341篇 |
2016年 | 349篇 |
2015年 | 373篇 |
2014年 | 459篇 |
2013年 | 608篇 |
2012年 | 938篇 |
2011年 | 953篇 |
2010年 | 453篇 |
2009年 | 384篇 |
2008年 | 604篇 |
2007年 | 550篇 |
2006年 | 485篇 |
2005年 | 465篇 |
2004年 | 355篇 |
2003年 | 282篇 |
2002年 | 249篇 |
2001年 | 43篇 |
2000年 | 14篇 |
1999年 | 25篇 |
1998年 | 32篇 |
1997年 | 15篇 |
1996年 | 12篇 |
1995年 | 12篇 |
1994年 | 8篇 |
1993年 | 6篇 |
1992年 | 5篇 |
1991年 | 10篇 |
1990年 | 4篇 |
1989年 | 4篇 |
1988年 | 2篇 |
1987年 | 3篇 |
1986年 | 9篇 |
1985年 | 2篇 |
1984年 | 3篇 |
1981年 | 2篇 |
1976年 | 3篇 |
1970年 | 1篇 |
1968年 | 2篇 |
1967年 | 1篇 |
1956年 | 3篇 |
1947年 | 1篇 |
1946年 | 1篇 |
1928年 | 1篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
91.
Stacy Schantz Wilkins PhD Rebecca J. Melrose PhD Katherine S. Hall PhD Erin Blanchard MS Steven C. Castle MD Teresa Kopp PT MBA Leslie I. Katzel MD PhD Alice Holder MHS PT Neil Alexander MD Michelle K.S. McDonald BA OT Arti Tayade MD CMD HMDC Daniel E. Forman MD Lauren M. Abbate MD PhD Rebekah Harris PT DPT PhDc Willy M. Valencia MD Miriam C. Morey PhD Cathy C. Lee MD 《Journal of the American Geriatrics Society》2021,69(4):1045-1050
92.
Brandon P. Verdoorn MD Tamara K. Evans BS Gregory J. Hanson MD Yi Zhu PhD Larissa G. P. Langhi Prata PhD Robert J. Pignolo MD PhD Elizabeth J. Atkinson MS Erin O. Wissler-Gerdes MA George A. Kuchel MD Joan B. Mannick MD Stephen B. Kritchevsky PhD Sundeep Khosla MD Stacey A. Rizza MD Jeremy D. Walston MD Nicolas Musi MD Lewis A. Lipsitz MD Douglas P. Kiel MD Raymond Yung MB ChB Nathan K. LeBrasseur PhD Ravinder J. Singh PhD Teresa McCarthy MD MS Michael A. Puskarich MD Laura J. Niedernhofer MD PhD Paul D. Robbins PhD Matthew Sorenson JD MA Tamara Tchkonia PhD James L. Kirkland MD PhD 《Journal of the American Geriatrics Society》2021,69(11):3023-3033
The burden of senescent cells (SnCs), which do not divide but are metabolically active and resistant to death by apoptosis, is increased in older adults and those with chronic diseases. These individuals are also at the greatest risk for morbidity and mortality from SARS-CoV-2 infection. SARS-CoV-2 complications include cytokine storm and multiorgan failure mediated by the same factors as often produced by SnCs through their senescence-associated secretory phenotype (SASP). The SASP can be amplified by infection-related pathogen-associated molecular profile factors. Senolytic agents, such as Fisetin, selectively eliminate SnCs and delay, prevent, or alleviate multiple disorders in aged experimental animals and animal models of human chronic diseases, including obesity, diabetes, and respiratory diseases. Senolytics are now in clinical trials for multiple conditions linked to SnCs, including frailty; obesity/diabetes; osteoporosis; and cardiovascular, kidney, and lung diseases, which are also risk factors for SARS-CoV-2 morbidity and mortality. A clinical trial is underway to test if senolytics decrease SARS-CoV-2 progression and morbidity in hospitalized older adults. We describe here a National Institutes of Health-funded, multicenter, placebo-controlled clinical trial of Fisetin for older adult skilled nursing facility (SNF) residents who have been, or become, SARS-CoV-2 rtPCR-positive, including the rationale for targeting fundamental aging mechanisms in such patients. We consider logistic challenges of conducting trials in long-term care settings in the SARS-CoV-2 era, including restricted access, consent procedures, methods for obtaining biospecimens and clinical data, staffing, investigational product administration issues, and potential solutions for these challenges. We propose developing a national network of SNFs engaged in interventional clinical trials. 相似文献
93.
94.
Infections with hepatitis C virus (HCV) represent a substantial national and international public health burden. HCV has been associated with numerous extrahepatic conditions and can lead to metabolic derangements that are associated with atherosclerosis and cardiovascular disease. We investigated whether HCV infection is associated with an increased number of acute coronary syndrome (ACS) events among hospitalized patients in an inner-city tertiary hospital.We performed a matched (age, sex, and race/ethnicity) case-control study on patients at least 18 years old admitted to inpatient medical and cardiac services at the University of Maryland Medical Center from 2015 through 2018. The primary outcome was ACS and the primary exposure was HCV infection. Covariates of interest included: alcohol use, tobacco use, illicit drug use, hypertension, diabetes mellitus, human immunodeficiency virus infection, body mass index, dyslipidemia, and family history of coronary heart disease. Covariates with significant associations with both exposure and outcome in bivariate analyses were included in the multivariable analyses of the final adjusted model.There were 1555 cases and 3110 controls included in the final sample. Almost 2% of cases and 2.4% of controls were HCV infected. In adjusted models, there was no significant association found between experiencing an ACS event in those with HCV infection compared to those without HCV infection (odds ratio 0.71, 95% confidence interval 0.45–1.11).We found no significant association between HCV infection and ACS in our study population. However, given the mixed existing literature, the association between HCV and ACS warrants further investigation in future prospective cohort and/or interventional studies. 相似文献
95.
Development and evaluation of a treatment fidelity instrument for family‐based treatment of adolescent anorexia nervosa 下载免费PDF全文
96.
97.
98.
Janet K. Freburger Dongmei Li Erin P. Fraher 《Archives of physical medicine and rehabilitation》2018,99(1):26-34.e5
Objectives
To determine whether receipt of therapy and number and timing of therapy visits decreased hospital readmission risk in stroke survivors discharged home.Design
Retrospective cohort analysis of Medicare claims (2010–2013).Setting
Acute care hospital and community.Participants
Patients hospitalized for stroke who were discharged home and survived the first 30 days (N=23,413; mean age ± SD, 77.6±7.5y).Interventions
Physical and occupational therapist use in the home and/or outpatient setting in the first 30 days after discharge (any use, number of visits, and days to first visit).Main Outcome Measures
Hospital readmission 30 to 60 days after discharge. Covariates included demographic characteristics, proxy variables for functional status, hospitalization characteristics, comorbidities, and prior health care use. Multivariate logistic regression analyses were conducted to examine the relation between therapist use and readmission.Results
During the first 30 days after discharge, 31% of patients saw a therapist in the home, 11% saw a therapist in an outpatient setting, and 59% did not see a therapist. Relative to patients who had no therapist contact, those who saw an outpatient therapist were less likely to be readmitted to the hospital (odds ratio, 0.73; 95% confidence interval, 0.59–0.90). Although the point estimates did not reach statistical significance, there was some suggestion that the greater the number of therapist visits in the home and the sooner the visits started, the lower the risk of hospital readmission.Conclusions
After controlling for observable demographic-, clinical-, and health-related differences, we found that individuals who received outpatient therapy in the first 30 days after discharge home after stroke were less likely to be readmitted to the hospital in the subsequent 30 days, relative to those who received no therapy. 相似文献99.
100.
Karen Charlton Marijka Batterham Kelly Langford Jenna Lateo Erin Brock Karen Walton Philippa Lyons-Wall Katie Eisenhauer Nick Green Cameron McLean 《Nutrients》2015,7(9):7126-7142
Impaired strength adversely influences an older person’s ability to perform activities of daily living. A cross-sectional study of 117 independently living men and women (age = 73.4 ± 9.4 year; body mass index (BMI) = 27.6 ± 4.8 kg/m2) aimed to assess the association between body composition and: (1) upper body strength (handgrip strength, HGS); (2) lower extremity performance (timed up and go (TUG) and sit to stand test (STS)); and (3) endurance (6-minute walk (SMWT). Body composition (% fat; lean body mass (LBM)) was assessed using bioelectrical impedance. Habitual physical activity was measured using the Minnesota Leisure Time Physical Activity Questionnaire (MLTPA) and dietary macronutrient intake, assessed using 24 h recalls and 3-day food records. Regression analyses included the covariates, protein intake (g/kg), MLTPA, age and sex. For natural logarithm (Ln) of right HGS, LBM (p < 0.001) and % body fat (p < 0.005) were significant (r2 = 46.5%; p < 0.000). For left LnHGS, LBM (p < 0.000), age (p = 0.036), protein intake (p = 0.015) and LnMLTPA (p = 0.015) were significant (r2 = 0.535; p < 0.000). For SMW, % body fat, age and LnMLTPA were significant (r2 = 0.346; p < 0.000). For STS, % body fat and age were significant (r2 = 0.251; p < 0.000). LBM is a strong predictor of upper body strength while higher % body fat and lower physical activity are associated with poorer outcomes on tests of lower extremity performance. 相似文献